Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPDC-T cells + interferon alfa-2a (The Third Affiliated Hospital of Sun Yat-sen University)
- Development stage
- Unknown
- Lead developer
- The Third Affiliated Hospital of Sun Yat-sen University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Interferons → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
HPDC-T cells + interferon alfa-2a is an investigational combination immunotherapy being developed for the treatment of chronic hepatitis B (CHB). The therapy consists of autologous dendritic cells (DCs) that are pulsed ex vivo with the Hepatitis B vaccine (HBsAg) to activate and expand antigen-specific T cells. These activated T cells (HPDC-T cells) are then reinfused into the patient to restore the defective HBV-specific cellular immune response. This cell-based component is combined with interferon alfa-2a, a recombinant cytokine that exerts broad antiviral and immunomodulatory effects. The combination aims to enhance the clearance of HBV by simultaneously stimulating innate immune signaling and restoring adaptive T-cell immunity. It has been evaluated in Phase 1/2 clinical trials by the Third Affiliated Hospital of Sun Yat-sen University, specifically targeting patients with suboptimal responses to standard nucleoside/nucleotide analog therapies.
- Brand names
- Roferon-A
- Other names
- Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV DrugsHepatitis B Vaccine-Pulsed Dendritic Cells and their induced T cells + Interferon alpha-2a
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on HPDC-T cells + interferon alfa-2a (The Third Affiliated Hospital of Sun Yat-sen University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPDC-T cells + interferon alfa-2a (The Third Affiliated Hospital of Sun Yat-sen University).